Hypofractionated Radiation Therapy for Breast Ductal Carcinoma In Situ

Hathout, Lara; Hijal, Tarek; Théberge, Valérie; Fortin, B.; Vulpe, Horia; Hogue, Jean-Charles; Lambert, Christine; Bahig, Houda; Provencher, Louise; Vavassis, Peter; Yassa, M.

doi:10.1016/j.ijrobp.2013.08.026

Cited by 38 publications

(35 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of them, 29 studies were considered as potentially eligible, while 12 met the C. Nilsson, A. Valachis / Radiotherapy and Oncology 114 (2015) 50-55 51 inclusion criteria for the present study [25][26][27][28][29][30][31][32][33][34][35][36]. One additional eligible study that was presented only in scientific meeting was included in the meta-analysis [37].…”

Section: Searching Resultsmentioning

confidence: 99%

The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: A meta-analysis of observational studies

Nilsson

Valachis

2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

Section: Searching Resultsmentioning

confidence: 99%

The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: A meta-analysis of observational studies

Nilsson

Valachis

2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

“…After a median follow-up time of 4.4 years, 14 patients out of 440 had an ipsilateral local relapse, resulting in a local recurrence free survival of 97% at 5 years. (57) In a population based analysis of 1,609 women with DCIS treated with BCS and RT in Ontario from 1994-2003, 60% received conventional RT and 40% received a HF regimen. The 10-year actuarial recurrence free survival rate was 86% among women treated with conventional RT and 89% for those treated with HF regimen (p=0.03).…”

Section: Particular Aspects Of Rt In Dcismentioning

confidence: 99%

Radiation Therapy Following Breast Conserving Surgery for Ductal Carcinoma in situ: Yes or No?

Stoleru¹,

Stoleru²

2017

chr

View full text Add to dashboard Cite

RezumatCarcinomul ductal in situ al sânului este un precursor non-invaziv al cancerului mamar şi este reprezentat de un grup de leziuni cu potenţial malign variabil. Tratamentul local optim pentru pacientele cu carcinom ductal in situ rãmane un subiect controversat, în ciuda rezultatelor provenite din mai multe trialuri randomizate. Radioterapia care urmeazã intervenţiei chirurgicale conservatoare reduce aproximativ la jumãtate riscul de recidivã localã, dar nu are impact în ceea ce priveşte supravieţuirea pe termen lung. Studiile clinice desfãşurate pânã în prezent nu au putut identifica un subgrup de paciente cu carcinom ductal in situ cu risc scãzut, la care sã se poata renunţa în siguranţã la radioterapie, dupã intervenţia chirurgicala conservatoare. În lucrare sunt prezentate rezultate ale studiilor clinice în care s-a utilizat chirurgia conservatoare a sânului urmatã sau nu de radioterapie. Alte subiecte abordate se referã la stabilirea indicaţiei terapeutice în cazul carcinomului ductal in situ cu risc scãzut şi la noi tendinţe în radioterapia pentru carcinomul ductal in situ. Review Articlebreast cancerand represents a heterogenous group of lesions with different malignant potential. Despite several randomized trials, there is still controversy regarding the optimal local treatment for DCIS patients. The addition of radiotherapy after breast conserving surgery approximately halves the local recurrence risk but has no impact on long-term survival. Clinical studies failed to identify a low risk subgroup of DCIS patients treated with breast conserving surgery in whom radiotherapy can be safely omitted. Results of clinical trials of breast conserving surgery ± radiotherapy are summarized. Treatment decision making in low risk DCIS and current tendencies in the radiotherapy for DCIS are other issues addressed in this paper.

show abstract

“…In a multicenter retrospective study from Canada, Hathout et al [34] observed a 5-year LR rate of around 3% in 440 women using the Whelan regimen of 42.5 Gy delivered in 16 fractions. Lalani et al [35] performed a population-based analysis of 1,609 patients from the Ontario Cancer Registry.…”

Section: Hypofractionationmentioning

confidence: 99%

Radiotherapy of Ductal Carcinoma In Situ

Krug

Souchon

2015

Breast Care

View full text Add to dashboard Cite

Ductal carcinoma in situ (DCIS) is a heterogeneous disease in both its biology and clinical course. In the past, recurrence rates after breast-conserving surgery have been as high as 30% after 10 years. The introduction of mammography screening and advances in imaging have led to an increase in the detection of DCIS. The focus of this review is on the role of radiotherapy in the multidisciplinary treatment, including current developments in hypofractionation and boost delivery, and attempts to define low-risk subsets of DCIS for which the need for adjuvant radiation is repeatedly questioned.

show abstract

Hypofractionated Radiation Therapy for Breast Ductal Carcinoma In Situ

Cited by 38 publications

References 28 publications

The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: A meta-analysis of observational studies

The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: A meta-analysis of observational studies

Radiation Therapy Following Breast Conserving Surgery for Ductal Carcinoma in situ: Yes or No?

Radiotherapy of Ductal Carcinoma In Situ

Contact Info

Product

Resources

About